Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lurasidone filed with EMA for schizophrenia

This article was originally published in Scrip

Executive Summary

Dainippon Sumitomo Pharma (DSP) has said that the European Medicines Agency (EMA) has accepted for review Takeda's marketing authorisation application (MAA) for the oral atypical antipsychotic, lurasidone hydrochloride, for the treatment of schizophrenia.The once-daily medication was discovered and developed by DSP and licensed to Takeda in March 2011, granting the latter exclusive commercialisation rights for lurasidone in 26 EU member states (excluding the UK), and Switzerland, Norway, Turkey and Russia. (The companies undertook joint responsibility for the drug's development.)


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts